July 2024
Canaan Partners Raises Additional $100M for Biotech Investments, Adds Pfizer Vet Uwe Schoenbeck
Canaan Partners, Biotech investments, Venture capital, Pfizer, Uwe Schoenbeck, Biopharma, Healthcare, Venture partner
Biopharma Layoff Tracker 2024: Industry-Wide Job Cuts Continue
Biopharma, Layoffs, Job Cuts, Industry Tracker, 2024
Biopharma Layoff Tracker 2024: Merck, Rapt, Aslan and More Cut Staff
Biopharma, Layoffs, Merck, Rapt, Aslan, Pharmaceutical Industry, Job Cuts, Restructuring
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Pfizer’s Hemophilia A Gene Therapy Candidate Achieves Phase 3 Success
Pfizer, Hemophilia A, Gene Therapy, Phase 3 Trial, Giroctocogene Fitelparvovec, Bleeding Rate Reduction
Telix Pharmaceuticals Raises $400M in Bond Sale Amid IPO Uncertainty
Telix Pharmaceuticals, Bond Sale, IPO, Radiopharma, Funding
Third Arc Bio Debuts with $165M Funding and Former J&J Executives at the Helm
Third Arc Bio, J&J, biotech, funding, executives, cancer, immune disease
Merck’s Investigational RSV Antibody, Clesrovimab, Meets Primary Safety and Efficacy Endpoints in Phase 2b/3 Trial for Infant Prevention
Merck, RSV, Clesrovimab, Monoclonal Antibody, Infant Prevention, Respiratory Syncytial Virus, Phase 2b/3 Trial
Bluebird Bio’s Fertility Support Program for Gene Therapies Rejected by HHS Inspector General
Bluebird Bio, Gene Therapy, Fertility Support, HHS Inspector General, Zynteglo, Skysona, Anti-Kickback Rules
Fierce Biotech Layoff Tracker 2024: Industry-Wide Job Cuts Continue
Biotech Layoffs, 2024, MEI Pharma, Rapt Therapeutics, Industry Cuts